Special Article. A Controlled Trial of Inpatient and Outpatient Geriatric Evaluation and Management. Harvey Jay Cohen, M.D., John R. Feussner, M.D., Morris Weinberger, Ph.D., Molly Carnes, M.D., Ronald C. Hamdy, M.D., Frank.
Standard- vs High- Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: Â Â The GRAVITAS Randomized Trial | Mar 1. JAMACorresponding Author: Matthew J. Price, MD, 1. 06.
Aconitum ferox (syn. A. virorum) is a member of the monkshood genus Aconitum of the Ranunculaceae. The common name by which it is most often known in English is Indian Aconite. The plant grows abundantly at Sandakphu, which is. Hears appeals of cases decided by executive branch agencies and federal trial courts in nine western states and two Pacific Island jurisdictions.
N Torrey Pines Rd, Maildrop S1. La Jolla, CA 9. 20. Author Contributions: Dr Price had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Price, Berger, Cannon, Angiolillo, Topol. Acquisition of Data: Price, Berger, Teirstein, Tanguay, Angiolillo, Spriggs, Puri, Robbins, Garratt, Bertrand, Stillabower, Aragon, Manoukian. Analysis and Interpretation of the data: Price, Berger, Cannon, Teirstein, Angiolillo, Schork, Topol.
Drafting of the manuscript: Price. Critical revision of the manuscript for important intellectual content: Price, Berger, Cannon, Teirstein, Tanguay, Angiolillo, Topol, Schork, Spriggs, Puri, Robbins, Garratt, Bertrand, Stillabower, Aragon, Stinis, Kandzari, Lee, Manoukian. Statistical analysis: Price, Schork.
Cheema California Trial Brief
Obtained funding: Price, Topol. Study supervision: Price, Berger, Cannon, Tanguay, Teirstein, Topol.
Dina is a legal strategist and trial attorney who honors responsive client service as a top priority. Dina has served as lead counsel in numerous lawsuits and bet-the-company litigation involving multi-million dollar claims. Business School, MBA, Executive Education, Executive Program, Kellogg School of Management, Gregory Carpenter, James Farley/Booz Allen Hamilton Professor of Marketing Strategy; Director of the Center for Market Leadership. Learn how a man with only 7 natural teeth in his mouth was promised a beautiful set of upper and lower fixed porcelain bridges. How? By putting in 20 dental implants. That's only the beginning of this botched dental. Ryan Charette, MD. Undergraduate: University of Connecticut. Medical School: University of Connecticut School of Medicine. Adnan Cheema, MD. Undergraduate: University of Missouri-Kansas. Medical School: University of Missouri. 1. JAMA. 2011 Mar 16;305(11):1097-105. doi: 10.1001/jama.2011.290. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. Price MJ(1. Research from JAMA — Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention — The GRAVITAS Randomized Trial.
Cheema California Trial Court
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Price reported receiving consulting fees from Bristol- Myers Squibb/sanofi- aventis, Daiichi Sankyo/Eli Lilly & Co, Accumetrics, Astra.
Zeneca, and Medicure; speakers fees from Daiichi Sankyo/Eli Lilly & Co; and grant support from Bristol- Myers Squibb/sanofi- aventis. Dr Tanguay reported receiving consulting and speakers fees from Bristol- Myers Squibb/sanofi- aventis, Daiichi Sankyo/Eli Lilly & Co, Glaxo. Smith. Kline, Abbott Vascular, and Astra. Zeneca and speakers fees from Boehringer Ingelheim. Dr Angiolillo reported receiving consulting fees from Bristol- Myers Squibb/sanofi- aventis, Daiichi Sankyo/Eli Lilly & Co, Astra. Zeneca, The Medicines Company, Portola, Novartis, Medicure, Accumetrics, Arena Pharmaceuticals, and Merck; and speakers fees from Bristol- Myers Squibb/sanofi- aventis and Daiichi Sankyo/Eli Lilly & Co; Dr Garratt reported receiving consulting fees from The Medicines Company; speakers fees from Boston Scientific, The Medicines Company, sanofi- aventis, Daiichi Sankyo/Eli Lilly & Co, Medtronic, and Abbott Vascular; and serving on the advisory board of Boston Scientific.
Dr Aragon reported receiving consulting and speakers fees from The Medicines Company, and speakers fees from Bristol- Myers Squibb/sanofi- aventis. Dr Kandzari reported receiving consulting and speakers fees from Daiichi Sankyo/Eli Lilly & Co. Dr Lee reported receiving speakers fees from Bristol- Myers Squibb/sanofi- aventis. Dr Cannon reports receiving consulting fees from Bristol- Myers Squibb/sanofi- aventis, Alynlam, and Novartis and grant support from Intekrin Therapeutics; and serving on the advisory board for Glaxo.
Smith. Kline and Merck. Dr Topol reported receiving consulting fees from Bristol- Myers Squibb/sanofi- aventis and Daiichi Sankyo/Eli Lilly & Co. The other authors reported no disclosures. Funding/Support: The GRAVITAS trial was funded by Accumetrics. The study drug was provided by an investigator- initiated grant from Bristol- Myers Squibb/sanofi- aventis.
Role of the Sponsor: The executive committee, consisting of both academic members and nonvoting representatives of the sponsor, designed and oversaw the conduct of the trial. The sponsor coordinated the data management with a contract research organization (Synteract, Carlsbad, California). Bristol- Myers Squibb/sanofi- aventis had no role in the design and management of the trial or in the analysis of the data. GRAVITAS Investigators: D.
Spriggs, S. Puri, M. Robbins, P. Teirstein, K. Garratt, O. Bertrand, M. Stillabower, J. Aragon, E. D. Nukta, J. F. Tanguay, A. Abbas, T. Mann, W.
Batchelor, P. Gordon, M. Schwieger, M. Amine, P.
Berger, N. Chronos, D. So, R. Stoler, S.
Marshalko, R. Waksman, C. Oâ€™Shaughnessy, E.
Fry, D. Angiolillo, B. Mc. Laurin, S. Rao, R.
Gammon, M. Z. Jafar, G. Wong, D. Cohen, J.
Robb, M. Lucca, S. Ward, D. Rizik, J. Wang, R. Minutello, E.
Mahmud, P. K. Cheung, M. Fugit, G. Mishkel, A. Jacobs, C. Meritt, M. Lurie, S. Manoukian, M. Turco, J. P. Reilly, M. Buchbinder, H. Herrmann, M. Vidovich, D. Purdy, M.
Warshofsky, J. Saucedo, L. Cannon, S. Waxman, G. Goulet, H. B. Cheek, R. Applegate, D. Simon, S. Plante, H. Aronow, V.
Misra, S. Mehta, A. Malik, S. Bailey, A. Cheema, J. Nappi, D. Abbott, J. Kao, O. Gigliotti, S. De. Maio, T. Mc. Garry, A.
Wu, D. Henderson, E. Schampaert, J. Joye, T. Huynh, J. P. Pelletier, D. Kereiakes, N. Kleiman, L. Bellumkonda, L. Gruberg. Previous Presentation: This study was presented as a late- breaking clinical trial at the American Heart Association Scientific Sessions, Chicago, Illinois, November 1.
This article was corrected for errors on May 2, 2.